BiotechTube

Istradefylline (KW-6002)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Nov 1, 2005 → Oct 1, 2006

NCT ID
NCT00250393

About Istradefylline (KW-6002)

Istradefylline (KW-6002) is a phase 2 stage product being developed by Kyowa Kirin for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00250393. Target conditions include Parkinson's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (8)

NCT IDPhaseStatus
NCT00250393Phase 2Completed
NCT00199446Phase 2Completed
NCT00199433Phase 2Completed
NCT00199355Phase 2Completed
NCT00199394Phase 3Completed
NCT00199420Phase 3Completed
NCT00199407Phase 3Completed
NCT00456794Phase 2Completed

Competing Products

20 competing products in Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 3
77
PerampanelEisaiPhase 2
52

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85